View our

CLINICAL TRIALS

Clinical Trials for

Acute Lymphoblastic Leukemia

Clinical Trials for

Acute Myeloid Leukemia

Clinical Trials for

Adrenoleukodystrophy (ALD)

Clinical Trials for

Chronic Myeloid Leukemia

Clinical Trials for

Ewing Sarcoma

Clinical Trials for

Fanconi Anemia

Clinical Trials for

Hemophagocytic Lymphohistiocytosis (HLH)

Clinical Trials for

Hepatoblastoma

Clinical Trials for

Juvenile Myelomonocytic Leukemia

Clinical Trials for

Kidney Tumors

  • AREN03B2 – Renal Tumors Biology Studies

Clinical Trials for

Metachromatic Leukodystropy (MCLD)

Clinical Trials for

Neuroblastoma

  • ANBL1531 – A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
  • ANBL1232 – Utilizing Response & Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma
  • ANBL00B1 – Neuroblastoma biology studies

Clinical Trials for

Non-Hodgkins Lymphoma (Burkitt, Large Cell, Lymphoblastic, Anaplastic)

  • NYMC 190 A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients WithRelapsed or Refractory Mature B-cell non-Hodgkin Lymphoma
  • NYMC 542 – A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma
  • ANHL12P1 – A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117
  • AALL1231 – A Phase III Randomized Trial Investigating Bortezomib on a Modified Augmented BFM Backbone in Newly Diagnosed T-Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma
  • ALTE11C1 – Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma
  • NYMC 166 – ImmunoChemotherapy with Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in children, adolescents and young adults with recurrent refractory CD20+ mature B-NHL
  • NYMC 157 – Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults with CD20+ Mature B-Cell Lymphoma
  • NYMC 542 – A Pilot Study of Mitozantrone in Combination with Clofarabone (MITCL) in Children Adolescents and Young Adults (CAYA) with Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma.
  • NYMC 172 – Childhood, Adolescent, and Young Adult (CAYA) Lymphoma/Leukemia Tissue Banking and Biorepository Center (BRC): CAYA L/L BRC

Clinical Trials for

Retinoblastoma

  • ARST1431 – A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Clinical Trials for

Servere Combined Immunodeficiency

Clinical Trials for

Solid Tumors

Clinical Trials for

Thalassemia

Clinical Trials for

Wellness and Survivorship

  • NYMC 168 – Cancer and Blood Marrow Transplantation Wellness and Survivorship Research

Clinical Trials for

Wilms Tumor

  • CCG4914L – National Wilms Tumor Late Effects Study

Clinical Trials for

Wiskott-Aldrich

Clinical Trials for

Other

  • APEC14B1- Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
  • ARST1431 – A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
  • AGCT1531 – A Phase 3 Study of Active Surveillance for Low risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
  • APEC1621SC – NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
  • ACNS1422 – A Phase 2 Study of Reduce Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
  • ACCL1633 – The Effectiveness of Lactobacillus plantarum (LBP, IND #17339) In preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
  • NYMC 573 Single Arm Study to Assess the Safety and Efficacy of Extracorporeal Photopheresis (ECP) in Conjunction with Prednisone in Children, Adolescents and Young Adults (CAYA) with Newly Diagnosed Acute Graft Versus Host Disease (AGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT)
  • NYMC 579 A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection with Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs) in Children, Adolescents and Young Adult Recipients
  • NYMC 580 A Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections with Related Donor CMV Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients
  • NYMC 581 A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection with Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients
  • NYMC 197 Safety and Tolerability of Chronic Erythrocytapheresis in Children, Adolescents and Young Adults (CAYA) Patients Receiving Chronic RBC Transfusions
  • NYMC 191 A Pilot Study of an Oral Anticoagulant “Apixaban” for the Treatment of Venous Thromboembolism in Children and Adolescents
  • NYMC 182 An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
  • NYMC 200 Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients With Solid Or Hematologic Malignancies That Harbor A Crizotinib-Sensitive Molecular Alteration But Who Are Unable To Swallow Crizotinib Capsules
    NYMC 196 PCYC-1140-IM  / A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects  with New Onset Chronic Graft Versus Host Disease (cGVHD)